PXT3003

Phase 2Small molecule

TTasly GeneNet Pharmaceuticals Co., Ltd

PXT3003 is one of 4 small molecule programs targeting Charcot-Marie-Tooth disease type 1A. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Charcot-Marie-Tooth Disease Type 1aActive, not recruiting

Charcot-Marie-Tooth Disease Type 1aPhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Charcot-Marie-Tooth Disease Type 1a

#DrugCompanyPhaseTrials

Cecon

MMcGuff Pharmaceuticals, Inc.

Ulipristal Acetate

PXT3003

TTasly GeneNet Pharmaceuticals Co., Ltd

Phase 2

2 4

EN001

EENCell

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy and Safety2 trials

Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)

Completed·UUnknown Sponsor·Phase 3·NCT02579759·323 enrolled

A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A

Completed·TTasly GeneNet Pharmaceuticals Co., Ltd·Phase 3·NCT05092841·176 enrolled

Charcot-Marie-Tooth disease type 1A2 trials

Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A

Completed·UUnknown Sponsor·Phase 2·NCT01401257·80 enrolled

Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A

Unknown status·UUnknown Sponsor·Phase 3·NCT03023540·187 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for PXT3003. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PXT3003 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PXT3003. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tasly GeneNet Pharmaceuticals Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTasly GeneNet Pharmaceuticals Co., Ltd

PXT3003

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Efficacy and Safety2 trials

Charcot-Marie-Tooth disease type 1A2 trials

References

Drug Info

Quick Facts

Related News